Our case is the first and most noteworthy case of a patient with metastatic colorectal cancer and a <i>HER2 L726I</i> mutation who achieved a remarkable clinical response to fam-trastuzumab deruxtecan. This evidence concerns the gene ERBB2 and metastatic colorectal cancer.